Cholangiocarcinoma
Conditions
Brief summary
sensitivity, specificity, positive predictive value, negative predictive value
Detailed description
True change and virtual change, Number of times readers’ conclusions differed, Cost-effectiveness analysis, budget impact analysis (BIA), sector costs, societal costs, health-related quality of life (HRQoL), Number of additional significant findings, Number of days between date of first imaging (CT/MRI) and starting date of chemotherapy, palliative therapy or surgical resection, The incidence and severity of AEs and SAEs according to CTCAEv5, Volume of interest (VOI), time to peak(TTP), K1 and K2, standardize uptake value (SUV), tumor-to-background ratio (TBR)
Interventions
DRUGGlucaGen®
DRUGHypoKit met 1 mg poeder en oplosmiddel voor oplossing voor injectie
DRUGScopolamine butylbromide Kalceks 20 mg/ml oplossing voor injectie
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sensitivity, specificity, positive predictive value, negative predictive value | — |
Secondary
| Measure | Time frame |
|---|---|
| True change and virtual change, Number of times readers’ conclusions differed, Cost-effectiveness analysis, budget impact analysis (BIA), sector costs, societal costs, health-related quality of life (HRQoL), Number of additional significant findings, Number of days between date of first imaging (CT/MRI) and starting date of chemotherapy, palliative therapy or surgical resection, The incidence and severity of AEs and SAEs according to CTCAEv5, Volume of interest (VOI), time to peak(TTP), K1 and K2, standardize uptake value (SUV), tumor-to-background ratio (TBR) | — |
Countries
Netherlands
Outcome results
None listed